DocWire News Editors

DocwireNews

Apixaban was linked with lower bleeding in patients with <a href="https://www.docwirenews.com/docwire-pick/cardiology-picks/dual-therapy-beats-triple-therapy-for-bleeding-afib/">atrial fibrillation</a> (AFib) and chronic kidney disease than warfarin, new study results suggest.&ldquo;Compared with the general population, patients with advanced chronic kidney disease have a &gt;10-fold higher burden of atrial fibrillation,&rdquo; the authors wrote in their paper. &ldquo;Limited data are available guiding the use of nonvitamin K antagonist oral anticoagulants in this population.&rdquo;The team enrolled 269 patients with AFib and advanced chronic kidney disease from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation(ARISTOTLE) trial and compared the safety of apixaban with that of warfarin. The used Cox proportional models to estimate hazard ratios for major bleeding as well as major or clinically relevant nonmajor bleeding. The pharmacokinetic profile of apixaban was characterized by the assessment of differences in exposure using nonlinear mixed effects models.<a style="color: #3366ff;" href="https://mashupmd.com/category/cardiology-news-and-journ/">For More Cardiology News from the most trusted sources, ACC, AHA and more click here</a>According to the results, among patients with a creatinine clearance of 25 mL/min to 30 mL/min, apixaban was associated with less major bleeding and major bleeding (HR=0.34; 95% CI, 0.14 to 0.80) and major or clinically relevant nonmajor bleeding (HR=0.35; 95% CI, 0.17 to 0.72) than warfarin. Those taking apixaban trended towards lower rates of major bleeding compared with those with creatinine clearance &gt;30 mL/min (P for interaction=0.08) and major or clinically relevant nonmajor bleeding (P for interaction=0.05). Patients with creatinine clearance 25 mL/min to 30 mL/min who were administered apixaban 5 mg twice daily had median daily steady-state area under the curve of 5,512 ng/(mL&middot;h) compared with 3,406 ng(mL&middot;h) for patients with creatinine clearance &gt;30 mL/min.&ldquo;Among patients with atrial fibrillation and creatinine clearance 5 to 30 mL/min, apixaban caused less bleeding than warfarin, with even greater reductions in bleeding than in patients with creatinine clearance &gt;30 mL/min,&rdquo; the authors concluded. &ldquo;We observed substantial overlap in the range of exposure to apixaban 5 mg twice daily for patients with or without advanced chronic kidney disease, supporting conventional dosing in patients with creatinine clearance 25 to 30 mL/min. Randomized, controlled studies evaluating the safety and efficacy of apixaban are urgently needed in patients with advanced <a href="https://www.docwirenews.com/docwire-pick/patients-with-advanced-ckd-describe-emotional-impact-of-their-illness-and-treatment/">chronic kidney diseas</a>e, including those receiving dialysis.&rdquo;The study was published in <a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044059">Circulation</a>.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/hashtag/EditorsPick?src=hash&amp;ref_src=twsrc%5Etfw">#EditorsPick</a>: In patients with advanced CKD and Afib in <a href="https://twitter.com/hashtag/ARISTOTLE?src=hash&amp;ref_src=twsrc%5Etfw">#ARISTOTLE</a> trial, apixaban caused less bleeding than warfarin, potentially even at conventional dosing. Read more: <a href="https://t.co/wlz9rqSwKg">https://t.co/wlz9rqSwKg</a> <a href="https://twitter.com/hashtag/AHAJournals?src=hash&amp;ref_src=twsrc%5Etfw">#AHAJournals</a> <a href="https://twitter.com/DCRINews?ref_src=twsrc%5Etfw">@DCRINews</a> <a href="https://t.co/Agev0ULnqo">pic.twitter.com/Agev0ULnqo</a>
&mdash; Circulation (@CircAHA) <a href="https://twitter.com/CircAHA/status/1255572866579468295?ref_src=twsrc%5Etfw">April 29, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
for non-valvular AF in advanced CKD, apixaban may be safer than warfarin dosing at 5 mg BID unless 2/3 ARISTOTLE criteria are present: RCT data from ARISTOTLE <a href="https://twitter.com/DCRINews?ref_src=twsrc%5Etfw">@DCRINews</a> <a href="https://twitter.com/DukeKidney?ref_src=twsrc%5Etfw">@DukeKidney</a> <a href="https://t.co/EEOlJoiCbq">https://t.co/EEOlJoiCbq</a> and featured podcast article: <a href="https://t.co/2DvENiAFsK">https://t.co/2DvENiAFsK</a>
&mdash; John Stanifer (@4UrineFormation) <a href="https://twitter.com/4UrineFormation/status/1254871220459372546?ref_src=twsrc%5Etfw">April 27, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Apixaban Yields Lower Bleeding than Warfarin in AFib Patients with Chronic Kidney Disease

Atrial Fibrillation

Apixaban was linked with lower bleeding in patients with atrial fibrillation (AFib) and chronic kidney disease than warfarin, new study results suggest.
 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe